Delta-Fly Pharma Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	-	-	-	-	-	300
Revenue Growth	-	-	-	-	-	0%
Gross Profit	-	-	-	-	-	300
Selling, General & Admin	191	210	212	229	261	287
Research & Development	1,410	1,329	1,437	1,118	1,011	940
Other Operating Expenses	66	66	59	56	43	34
Operating Expenses	1,667	1,605	1,708	1,403	1,315	1,261
Operating Income	-1,667	-1,605	-1,708	-1,403	-1,315	-961
Currency Exchange Gain (Loss)	-2	-	-1	-5	-5	-
Other Non Operating Income (Expenses)	-9	-18	-10	-19	-5	-3
Pretax Income	-1,678	-1,623	-1,719	-1,427	-1,325	-964
Income Tax Expense	2	2	2	2	3	3
Net Income	-1,680	-1,625	-1,721	-1,429	-1,328	-967
Net Income to Common	-1,680	-1,625	-1,721	-1,429	-1,328	-967
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	12	12	9	7	6	5
Shares Outstanding (Diluted)	12	12	9	7	6	5
Shares Change	33.77%	31.55%	22.38%	26.91%	4.61%	17.64%
EPS (Basic)	-134.57	-140.37	-195.56	-198.72	-234.37	-178.52
EPS (Diluted)	-134.57	-140.37	-195.56	-198.72	-234.37	-178.52
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	-	-1,557	-1,834	-1,280	-1,303	-940
Free Cash Flow Per Share	-	-134.50	-208.41	-178.00	-229.96	-173.54
Gross Margin	-	-	-	-	-	100.00%
Operating Margin	-	-	-	-	-	-320.33%
Profit Margin	-	-	-	-	-	-322.33%
Free Cash Flow Margin	-	-	-	-	-	-313.33%
EBITDA	-1,666	-1,604	-1,707	-1,402	-1,314	-960
D&A For EBITDA	1	1	1	1	1	1
EBIT	-1,667	-1,605	-1,708	-1,403	-1,315	-961